Crk-like protein SH2 domain (CRKL SH2)

Crk-like protein (CRKL) is a pivotal adaptor protein that functions as a molecular bridge in various intracellular signaling pathways, primarily through its SH2 and SH3 domains (UniProt: P46109). The CRKL SH2 domain is specifically responsible for binding to phosphorylated tyrosine residues on upstream signaling molecules, such as the BCR-ABL oncoprotein in chronic myeloid leukemia (CML) and various receptor tyrosine kinases (PubMed: 15622163). In CML, CRKL is the most prominent substrate of BCR-ABL, and its SH2-mediated recruitment is essential for the activation of downstream pathways like Ras/MAPK and PI3K/Akt, which drive leukemogenesis (PubMed: 10449774). Beyond hematological malignancies, CRKL is frequently overexpressed in solid tumors, including lung and breast cancers, where it contributes to epithelial-mesenchymal transition and metastasis (PubMed: 24608500). While current therapies like Imatinib indirectly modulate CRKL by inhibiting BCR-ABL, the CRKL SH2 domain itself is an emerging therapeutic target for the development of small-molecule inhibitors and peptidomimetics designed to disrupt oncogenic protein-protein interactions (PubMed: 22490558). However, targeting this domain presents challenges due to the high structural homology among SH2 domains in the human proteome and the critical role of CRKL in normal development, as evidenced by its association with DiGeorge syndrome (PubMed: 11586300).

Other names

CrkLCrk-like proteinv-crk avian sarcoma virus CT10 oncogene homolog-likeCRKL SH2 domain

Disruption of protein-protein interactions by competitively binding to the phosphotyrosine-binding pocket of the SH2 domain, thereby preventing the recruitment of CRKL to oncogenic kinases like BCR-ABL.